

# Kishan S Parikh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2392839/publications.pdf>

Version: 2024-02-01

28  
papers

546  
citations

687363

13  
h-index

642732

23  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1002  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. <i>Journal of Cardiac Failure</i> , 2021, 27, 942-948.                  | 1.7 | 0         |
| 2  | Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.   | 4.1 | 41        |
| 3  | Pulmonary Hypertension Subtypes and Mortality in CKD. <i>American Journal of Kidney Diseases</i> , 2020, 75, 713-724.   | 1.9 | 32        |
| 4  | Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. <i>Respiratory Research</i> , 2020, 21, 304.   | 3.6 | 3         |
| 5  | Experience in Transitioning From Parenteral Prostaglandins to Selexipag in Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 299-304.  | 1.9 | 8         |
| 6  | Applications of the Multisensor HeartLogic Heart Failure Monitoring Algorithm During the COVID-19 Global Pandemic. <i>JACC: Case Reports</i> , 2020, 2, 2265-2269.  | 0.6 | 9         |
| 7  | Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. <i>Chest</i> , 2019, 156, 1176-1186.  | 0.8 | 32        |
| 8  | Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2019, 124, 1298-1304.                                      | 1.6 | 13        |
| 9  | Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. <i>European Respiratory Journal</i> , 2019, 54, 1900831.   | 6.7 | 47        |
| 10 | Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. <i>Circulation: Heart Failure</i> , 2019, 12, e005171.  | 3.9 | 15        |
| 11 | Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. <i>Respiratory Medicine</i> , 2019, 150, 126-130.  | 2.9 | 12        |
| 12 | Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. <i>Scientific Reports</i> , 2019, 9, 4061.   | 3.3 | 36        |
| 13 | Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 1056-1065.   | 4.1 | 21        |
| 14 | Cardiac Rehabilitation After Ventricular Assist Device Implantation. <i>JACC: Heart Failure</i> , 2018, 6, 140-142.   | 4.1 | 0         |
| 15 | Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins. <i>American Heart Journal</i> , 2018, 196, 131-143. | 2.7 | 17        |
| 16 | Dose Response of $\beta$ -Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002210.  | 3.6 | 8         |
| 17 | Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.  | 4.1 | 103       |
| 18 | Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.   | 1.6 | 16        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. <i>Circulation</i> , 2017, 135, 2077-2080.  | 1.6 | 28        |
| 20 | Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1683-1691.  | 2.8 | 45        |
| 21 | Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 529-535.   | 3.3 | 2         |
| 22 | Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. <i>Epidemiology</i> , 2017, 28, 740-746.   | 2.7 | 1         |
| 23 | Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 322-325.  | 1.9 | 12        |
| 24 | Mode of Death After Acute Heart Failure Hospitalization—A Clue to Possible Mechanisms. <i>Circulation Journal</i> , 2016, 80, 17-23.   | 1.6 | 13        |
| 25 | Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). <i>American Journal of Cardiology</i> , 2016, 118, 1211-1216. | 1.6 | 11        |
| 26 | Use of outcome measures in pulmonary hypertension clinical trials. <i>American Heart Journal</i> , 2015, 170, 419-429.e3.  | 2.7 | 17        |
| 27 | PH Grand Rounds: Confronting the Challenge of Sarcoidosis-Associated Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 166-169.  | 0.1 | 0         |
| 28 | Potential Applications of Pharmacogenomics to Heart Failure Therapies. <i>Heart Failure Clinics</i> , 2014, 10, 599-606.   | 2.1 | 4         |